Amorphous rosuvastatin calcium tablets offer improved bioavailability and cost-effectiveness for treating dyslipidaemia. Utilizing direct compression technology, the formulation integrates superdisintegrants and carefully chosen excipients to ensure rapid disintegration and dissolution. The amorphous form provides superior solubility despite lower stability compared to crystalline variants. Characterization methods, such as PXRD and TGA, confirmed the stability and suitability of the excipient-active ingredient combination, ensuring consistent and effective drug performance.
González, R., Peña, M.Á., Torres, N.S., and Torrado, G., 2022. Design, development, and characterization of amorphous rosuvastatin calcium tablets. PLoS One
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Rosuvastatin 10 by Swiss Remedies, consult with your doctor or healthcare professional.
González, R., Peña, M.Á., Torres, N.S., and Torrado, G., 2022. Design, development, and characterization of amorphous rosuvastatin calcium tablets. PLoS One
González, R., Peña, M.Á., Torres, N.S., and Torrado, G., 2022. Design, development, and characterization of amorphous rosuvastatin calcium tablets. PLoS One
González, R., Peña, M.Á., Torres, N.S., and Torrado, G., 2022. Design, development, and characterization of amorphous rosuvastatin calcium tablets. PLoS One